Key Points
- CFO Matthew Szot sold 9,933 shares on Dec. 29 at an average price of $6.97 for a total of $69,233, a transaction disclosed in an SEC filing.
- Citadel Advisors bought a new stake of 19,864 shares (about $274,000), owning 0.96% of Cadrenal at quarter end, while institutional investors hold 7.92% of the stock.
- Cadrenal is a small-cap clinical-stage biopharma (market cap ~$15.87M) trading near its 12‑month low with negative earnings—Q3 EPS was ($1.31), beating estimates—and analysts forecast -7.59 EPS for the year with a consensus rating of Hold (average target $32.00).
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the firm's stock in a transaction on Monday, December 29th. The stock was sold at an average price of $6.97, for a total value of $69,233.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Cadrenal Therapeutics Trading Up 2.4%
NASDAQ CVKD opened at $6.78 on Thursday. The stock has a 50-day simple moving average of $10.40 and a 200 day simple moving average of $11.80. The company has a market capitalization of $15.87 million, a PE ratio of -0.85 and a beta of 1.08. Cadrenal Therapeutics, Inc. has a 12 month low of $6.42 and a 12 month high of $22.90.
Cadrenal Therapeutics (NASDAQ:CVKD - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($1.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.55) by $0.24. As a group, sell-side analysts predict that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Cadrenal Therapeutics
A hedge fund recently bought a new stake in Cadrenal Therapeutics stock. Citadel Advisors LLC purchased a new position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 19,864 shares of the company's stock, valued at approximately $274,000. Citadel Advisors LLC owned 0.96% of Cadrenal Therapeutics at the end of the most recent quarter. Institutional investors own 7.92% of the company's stock.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Cadrenal Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Cadrenal Therapeutics has a consensus rating of "Hold" and an average target price of $32.00.
Get Our Latest Report on CVKD
About Cadrenal Therapeutics
(
Get Free Report)
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
